The Economic Simplification Act, published in the French Official Journal on May 27, 2026, aims to reduce administrative burdens affecting businesses, public institutions, and innovation stakeholders. Its objective is to accelerate economic projects by simplifying procedures, reducing administrative formalities, and promoting the use of digital tools.
The Economic Simplification Act covers a wide range of sectors, from industry and energy transition to digital technologies, innovation, and healthcare. Several of its provisions directly affect the clinical research ecosystem, particularly the reuse of health data, research involving human participants (RIPH), clinical trials, and the responsibilities of the French Data Protection Authority (CNIL).
For sponsors, CROs, healthcare institutions, and investigators, this regulatory development could help strengthen France’s attractiveness in an increasingly competitive European research environment.
What is the impact of the Economic Simplification Act on research involving human participants (RIPH)?
Reducing administrative complexity has long been a priority for both academic and industrial sponsors.
Research involving human participants is currently governed by a complex regulatory framework that includes:
- the French Jardé Law;
- Regulation (EU) No. 536/2014 on clinical trials for medicinal products;
- CNIL requirements regarding personal data protection;
- procedures involving the French Ethics Committees (Comités de Protection des Personnes – CPP);
- authorizations issued by the French National Agency for Medicines and Health Products Safety (ANSM), when applicable.
Without compromising participant safety, the Economic Simplification Act seeks to reduce administrative burdens in order to shorten project implementation timelines.
At a time when rapid study start-up has become a key factor in attracting international clinical research investments, these measures are being closely monitored by all stakeholders.
A stronger focus on innovation within the CNIL’s missions
Article 59 of the Economic Simplification Act also expands the missions of the French Data Protection Authority (CNIL).
The objective is to integrate innovation more explicitly into the way the authority carries out its responsibilities.
For projects involving artificial intelligence, large-scale health data, or digital technologies applied to clinical research, this evolution could improve the visibility of regulatory expectations while encouraging earlier dialogue between project sponsors and the data protection authority.
As the European AI Act and the European Health Data Space (EHDS) continue to be implemented, these changes are consistent with the European Union’s broader strategy to promote responsible healthcare innovation.
A broader strategy to strengthen France’s competitiveness
The Economic Simplification Act is also part of a broader national and European strategy aimed at making clinical research more attractive. In recent years, France has introduced several initiatives to shorten study start-up timelines, improve collaboration between competent authorities, and encourage innovation in healthcare. These efforts complement the implementation of the Clinical Trials Regulation (EU) No. 536/2014 and the deployment of the Clinical Trials Information System (CTIS), which have already contributed to harmonising clinical trial procedures across Europe.
For sponsors planning multinational clinical trials, greater administrative consistency and improved coordination between regulatory authorities could help reduce delays and facilitate the inclusion of French investigational sites in international research programmes. While these measures will not eliminate every operational challenge, they represent another step towards a more efficient and competitive clinical research environment.
Simplification must now deliver tangible results
Although the Economic Simplification Act represents another important step in France’s ambition to support healthcare innovation, its success will ultimately depend on its practical implementation. Future implementing measures, changes in administrative practices, and the way stakeholders adopt these new provisions will determine whether the expected benefits become reality.
For sponsors, CROs, healthcare institutions, and pharmaceutical or medical device companies, these regulatory changes also offer an opportunity to rethink internal processes in order to take full advantage of the new framework while maintaining high standards of quality, participant safety, and regulatory compliance.
As European countries continue to compete for international clinical trials, administrative simplification is only one element of France’s overall attractiveness. It must be supported by investments in research infrastructure, stronger investigator networks, better use of health data, and closer collaboration between public authorities, healthcare institutions, and industry.
The Economic Simplification Act therefore sends a positive signal to the French clinical research ecosystem, which is in real need of measures to strengthen its competitiveness. If the promised simplifications are effectively implemented, the Economic Simplification Act could help accelerate the development of innovative therapies and medical devices while facilitating patient access to clinical trials and tomorrow’s treatments.
